A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1879 participants.
Also called NCT03987919
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,879 participants
- Sponsor
- Registry
-
NCT03987919 -
2018-004422-29
-
- Other papers using this trial's data
- Bacillus Calmette-Guérin vaccine to reduce healthcare worker absenteeism in COVID-19 pandemic, a randomized controlled trial
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Brazil, Canada, Israel, Mexico, Puerto Rico, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03987919. Randomized; no masking; primary purpose treatment. Start 2019-07-30 (actual); primary completion 2021-01-28 (actual). Results posted on 2022-02-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
- Acronym
- SURPASS-2
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Tirzepatide
- Intervention (Drug)
- Semaglutide
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct03987919- Content hash
2c1a6b90d203851f9e20ed26902af6c2d990cebf6006262ff336cd80112c3492